## Comparative Effectiveness of BNT162b2 versus Ad26.COV2.S for the Prevention of

## **COVID-19 among Dialysis Patients**

Steven M. Brunelli, MSCE, MD<sup>1</sup>; Scott Sibbel, MPH, PhD<sup>1</sup>; Steph Karpinski, MS, MA<sup>1</sup>; Gilbert

Marlowe, BS<sup>1</sup>; Adam G. Walker, PhD<sup>1</sup>; Jeffrey Giullian, MD<sup>2</sup>; David Van Wyck, MD<sup>2</sup>; Tara

Kelley, MBA<sup>1</sup>; Rachael Lazar, MPH<sup>2</sup>; Meredith L. Zywno, MSPH<sup>2</sup>; Jeffrey J. Connaire, MD<sup>1</sup>;

Amy Young, BA<sup>1</sup>; Francesca Tentori, MS, MD<sup>1</sup>

## **Supplemental Table of Contents**

- 1. **Table S1**. Baseline comparison of all matched AD26.COV2.S and BNT162b2 patients
- 2. **Table S2**. Characteristics of Patients who were diagnosed with COVID-19 during at-risk time.

	BNT162b2 (N=2,732)	AD26.COV2.S (N=2,732)	Standardized mean difference
Site of dialysis <sup>c,d</sup>			+0.0%
In-center HD	87.7%	87.7%	
Home <sup>f</sup>	12.3%	12.3%	
Age <sup>d</sup> , y	$61.3 \pm 13.1$	$61.8\pm13.5$	+3.8%
Female <sup>d</sup>	40.6%	40.8%	+0.4%
Race/ethnicity <sup>d</sup>			+2.3%
White	31.8%	33.8%	
Af American	33.9%	32.7%	
LatinX	22.6%	21.3%	
Asian	3.3%	3.9%	
Other/unk	8.5%	8.3%	
Vintage <sup>d</sup> , y	2.7 [1.0, 5.3]	2.6 [1.0, 5.2]	-2.7%
Etiology of ESKD <sup>d</sup>			-1.9%
Diabetes	35.5%	35.0%	
Hypertension	25.1%	24.5%	
Other	39.4%	40.5%	
Diabetes <sup>d</sup>	67.4%	67.3%	-0.9%
CCI <sup>d</sup>	$4.9 \pm 1.6$	$4.9 \pm 1.5$	+0.0%
Prior transplant <sup>d</sup>	4.8%	4.5%	-1.4%
Prior COVID-19 <sup>c,d,e</sup>	10.5%	10.5%	+0.0%
Albumin <sup>d</sup> , g/dL	$4.1 \pm 0.4$	$4.1 \pm 0.4$	+0.0%
Creatinine, mg/dL	$8.6 \pm 3.3$	8.4 ± 3.2	-6.2%
Hemoglobin, g/dL	$10.7 \pm 1.4$	$10.6 \pm 1.4$	-7.1%
Ferritin, ng/ml	692 [423, 960]	700 [439, 961]	+2.2%
TSAT, %	27.3 ± 12.9	$26.9 \pm 13.0$	-3.1%
Phosphorus, mg/dL	$5.7 \pm 1.7$	5.6 ± 1.7	-5.9%
PTH, pg, ml	388 [250, 592]	379 [239, 575]	-4.4%
Household poverty <sup>g</sup> , %	$15.9 \pm 9.4$	15.1 ± 8.4	-9.0%
Housing vacancy <sup>g</sup> , %	$9.9\pm 6.5$	$10.2 \pm 6.4$	+4.7%
Unemployment <sup>g</sup> , %	$6.5 \pm 3.5$	6.1 ± 3.0	-12.3%
18-24 year olds without a	$13.9 \pm 7.6$	$13.9 \pm 7.7$	+0.0%
high school diploma <sup>g</sup> , %			
Index date <sup>c,d</sup>	21Mar [12Mar, 1Apr]	21Mar [12Mar, 1Apr]	+0.0%
State <sup>c,d</sup>			+0.0%
AL	2.3%	2.3%	
AR	1.6%	1.6%	
AZ	2.8%	2.8%	
CA	17.2%	17.2%	
СО	0.2%	0.2%	
СТ	0.2%	0.2%	
FL	5.7%	5.7%	
GA	3.6%	3.6%	
IA	0.3%	0.3%	
ID	<0.1%	<0.1%	
IL	11.7%	11.7%	
IN	0.1%	0.1%	

Table S1. Baseline comparison of all matched AD26.COV2.S and BNT162b2 patients. <sup>a,b</sup>

I/C	1 70/	1 70/	
KS	1.7%	1.7%	
KY	1.6%	1.6%	
LA	0.4%	0.4%	
MA	<0.1%	<0.1%	
MD	4.8%	4.8%	
ME	0.2%	0.2%	
MI	2.6%	2.6%	
MN	0.1%	0.1%	
МО	1.0%	1.0%	
NC	0.7%	0.7%	
NE	0.2%	0.2%	
NH	0.2%	0.2%	
NJ	5.6%	5.6%	
NM	0.2%	0.2%	
NV	1.1%	1.1%	
NY	2.8%	2.8%	
ОН	2.7%	2.7%	
OK	0.5%	0.5%	
OR	1.8%	1.8%	
PA	2.9%	2.9%	
SC	2.0%	2.0%	
TN	0.5%	0.5%	
TX	14.2%	14.2%	
UT	0.1%	0.1%	
VA	0.2%	0.2%	
WA	3.8%	3.8%	
WI	2.4%	2.4%	
WV	0.2%	0.2%	
a Demandation and a final and		0.270	

<sup>a</sup> Descriptions as of index date.
<sup>b</sup> Estimates presented as mean ± SD, median [p25, p75], or percentage.
<sup>c</sup> Included in propensity score model
<sup>d</sup> Matching factor
<sup>e</sup> Refers to COVID-19 prior to index date (date of first vaccination).
<sup>f</sup> Home includes both peritoneal dialysis and home hemodialysis

<sup>g</sup> Based on census level data linked through zip code

Abbreviations: y, year; ESKD, end-stage kidney disease; CCI, Charlson comorbidity index; TSAT, transferrin saturation; PTH, parathyroid hormone

	COVID-19 Diagnoses	
	(N=158)	
Site of dialysis	(1/ 130)	
In-center HD	84.8%	
Home <sup>d</sup>	15.2%	
	$61.1 \pm 12.1$	
Age, y		
Female	46.8%	
Race/ethnicity		
White	38.0%	
Af American	31.0%	
LatinX	23.4%	
Asian	1.9%	
Other/unk	5.7%	
Vintage, y	2.6 [1.1, 5.1]	
Etiology of ESKD		
Diabetes	41.8%	
Hypertension	22.8%	
Other	35.4%	
Diabetes	76.0%	
CCI	$5.0 \pm 1.5$	
Prior transplant	5.1%	
Prior COVID-19 °	0%	
Albumin, g/dL	$4.0 \pm 0.5$	
Creatinine, mg/dL	8.5 ± 3.2	
Hemoglobin, g/dL	$10.5 \pm 1.5$	
Ferritin, ng/ml	667 [424, 972]	
TSAT, %	$27.1 \pm 11.0$	
Phosphorus, mg/dL	$5.8 \pm 1.8$	
PTH, pg, ml	387 [259, 602]	
Household poverty °, %	15.7 ± 8.6	
Housing vacancy <sup>e</sup> , %	$10.5 \pm 7.9$	
Unemployment <sup>e</sup> , %	$6.3 \pm 2.9$	
18-24 year olds without a	$13.9 \pm 6.4$	
high school diploma <sup>e</sup> , %	15.7 ± 0.4	
Index date	23Mar [12Mar, 1Apr]	
US State		
AL	4.4	
AR	1.9	
AZ	0.6	
CA	19.0	
FL	8.2	
GA	4.4	
IA	0.6	
IL	9.5	
KS	1.9	
KY	3.2	
LA	0.6	
MD	2.5	
MI	1.3	
NC	0.6	
NJ	2.5	
NY	3.2	
OH	1.3	
OR	2.5	
	2.3	

Table S2. Characteristics of Patients who were diagnosed with COVID-19 during at-risk time. <sup>a,b</sup>

SC	5.1	
TN	1.3	
TX	20.9	
WA	3.2	
WI	0.6	
WV	0.6	

<sup>a</sup> Descriptions as of index date. <sup>b</sup> Estimates presented as mean ± SD, median [p25, p75], or percentage. <sup>c</sup> Refers to COVID-19 prior to index date (date of first vaccination). <sup>d</sup> Home includes both peritoneal dialysis and home hemodialysis <sup>e</sup> Based on census level data linked through zip code

Abbreviations: y, year; ESKD, end-stage kidney disease; CCI, Charlson comorbidity index; TSAT, transferrin saturation; PTH, parathyroid hormone